

6 December 2024

\$1.03m R&D Tax Incentive received

Perth, Australia, and Minneapolis, USA: TrivarX Limited ('the Company') (ASX: TRI) is pleased to confirm the receipt of \$1,031,073 for its Research & Development (R&D) Tax Incentive for the 2023/24 financial year.

The incentive relates to TrivarX's eligible expenditure in connection with the Company's recently completed Phase 2 Sleep Analysis of Major Depressive Episode (SAMDE) clinical study, work towards the Company's pending pivotal study and the ongoing development and commercialisation of its sleep staging software.

The Australian federal government's R&D Tax Incentive is an important program that encourages companies to engage in research and development benefitting Australia by providing a tax offset. Based on TrivarX's turnover, the tax offset was 43.5% of the expenditure on eligible activities.

Management commentary:

Non-Executive Chairman, Mr David Trimboli said: *"The Australian government's R&D program greatly assists companies like TrivarX to advance innovative solutions. These funds will provide the Company with exceptional financial flexibility, as it continues to commercialise its range of AI-backed solutions for mental health screening."*

This announcement is authorised for release by the Board of Directors of TrivarX Limited.

ENDS

Investor Enquiries:

Henry Jordan – Six Degrees Investor Relations

Henry.jordan@sdir.com.au

+61 431 271 538

About TrivarX Limited:

TrivarX (ASX: TRI) (OTCPINK: MDBIF) is a mental health technology company pioneering the use of objective measures to aid in the early detection and screening of mental health conditions. The Company was founded in Australia, with offices located in Perth (WA) and Minneapolis (MN, USA). TrivarX is listed on the Australian Securities Exchange Ltd and trades on the OTCQB Venture Market. Investors can find additional information on www.otcm Markets.com and www.asx.com.au